NAMS (NewAmsterdam Pharma Company N.V. Ordinary Shares) Stock Analysis

NewAmsterdam Pharma Company N.V. Ordinary Shares (NAMS) is a publicly traded Healthcare sector company. As of May 20, 2026, NAMS trades at $35.77 with a market cap of $3.99B and a P/E ratio of -20.07. NAMS moved +6.11% today. Year to date, NAMS is +6.78%; over the trailing twelve months it is +84.75%. Its 52-week range spans $14.06 to $42.21. Analyst consensus is strong buy with an average price target of $48.00. Rallies surfaces NAMS's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

What is the latest NAMS stock research?

NewAmsterdam Pharma Company N.V. Ordinary Shares (NAMS) research on Rallies includes live charts, financials, analyst ratings, hedge fund holdings, politician trades, insider activity, news, AI research, and community context. NAMS moved +6.11% today. Analyst consensus is strong buy.

NAMS Key Metrics

Key financial metrics for NAMS
MetricValue
Price$35.77
Market Cap$3.99B
P/E Ratio-20.07
EPS$-1.79
Dividend Yield0.00%
52-Week High$42.21
52-Week Low$14.06
Volume1.15M
Avg Volume0
Revenue (TTM)$22.57M
Net Income$-212.73M
Gross Margin0.00%

Latest NAMS News

Recent NAMS Insider Trades

  • LANGE LOUIS G sold 44.17K (~$1.34M) on Mar 11, 2026.
  • LANGE LOUIS G sold 446 (~$13.93K) on Mar 11, 2026.
  • Kastelein Johannes Jacob Pieter sold 101.41K (~$3.07M) on Mar 9, 2026.

NAMS Analyst Consensus

11 analysts cover NAMS: 0 strong buy, 10 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $48.00.

Common questions about NAMS

What can I research for NAMS on Rallies?
NewAmsterdam Pharma Company N.V. Ordinary Shares (NAMS) research on Rallies includes live charts, financials, analyst ratings, hedge fund holdings, politician trades, insider activity, news, AI research, and community context. NAMS moved +6.11% today. Analyst consensus is strong buy.
Does Rallies show live market data for NAMS?
Rallies combines live market context with ticker research for NAMS, including charts, news, financials, analyst data, institutional holdings, politician trades, insider activity, and AI research where available.
NAMS

NAMS